Temat: "IMMUNOSUPPRESSIVE agents" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: NEW CONNECTIONS.
Autorzy :: Frey, Scott H.; Pokaż więcej
Temat :: HAND transplants
IMMUNOSUPPRESSIVE agents
ORGANS (Anatomy)
BRAIN function localization
BLOOD flow
Źródło :: Scientific American. Dec2020, Vol. 323 Issue 6, p62-69. 8p. 2 Black and White Photographs, 2 Diagrams.
: Periodyk

Szczegóły Pełny tekst

Skocz do pozycji: 2 2.

Tytuł :: Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
Autorzy :: Stefanović NZ; Department of Pharmacy, Faculty of Medicine, University of Nis, Dr Zorana Djindjica 81 Blvd., 18000, Nis, Serbia. .
Veličković-Radovanović RM; Department of Pharmacology With Toxicology, Faculty of Medicine, University of Nis, Dr Zorana Djindjica 81 Blvd., , 18000, Nis, Serbia.; Clinic of Nephrology, Clinical Center Nis, Dr Zorana Djindjica 48 Blvd., 18000, Nis, Serbia.
Danković KS; Faculty of Medicine, University of Nis, Dr Zorana Djindjica 81 Blvd., 18000, Nis, Serbia.
Mitić BP; Clinic of Nephrology, Clinical Center Nis, Dr Zorana Djindjica 48 Blvd., 18000, Nis, Serbia.; Department of Internal Medicine, Faculty of Medicine, University of Nis, Dr Zorana Djindjica 81 Blvd., 18000, Nis, Serbia.
Paunović GJ; Clinic of Nephrology, Clinical Center Nis, Dr Zorana Djindjica 48 Blvd., 18000, Nis, Serbia.
Cvetković MB; Clinic of Nephrology, Clinical Center Nis, Dr Zorana Djindjica 48 Blvd., 18000, Nis, Serbia.; Faculty of Medicine, University of Nis, Dr Zorana Djindjica 81 Blvd., 18000, Nis, Serbia.
Cvetković TP; Clinic of Nephrology, Clinical Center Nis, Dr Zorana Djindjica 48 Blvd., 18000, Nis, Serbia.; Department of Biochemistry, Faculty of Medicine, University of Nis, Dr Zorana Djindjica 81 Blvd., 18000, Nis, Serbia.; Pokaż więcej
Źródło :: European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2020 Dec; Vol. 45 (6), pp. 749-760.
Typ publikacji :: Journal Article
MeSH Terms :: Cytochrome P-450 CYP3A/*genetics
Immunosuppressive Agents/*pharmacokinetics
Immunosuppressive Agents/*therapeutic use
Kidney Transplantation/*methods
Tacrolimus/*pharmacokinetics
Tacrolimus/*therapeutic use
ATP Binding Cassette Transporter, Subfamily B/genetics ; Adult ; Female ; Genotype ; Glomerular Filtration Rate ; Graft Survival ; Humans ; Immunosuppressive Agents/administration & dosage ; Isoenzymes/genetics ; Male ; Middle Aged ; Polymorphism, Genetic ; Retrospective Studies ; Tacrolimus/administration & dosage
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach.
Autorzy :: Barber MRW; University of Calgary, Alberta, Canada.
Hanly JG; Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
Su L; University of Cambridge, Cambridge, UK.
Urowitz MB; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
St Pierre Y; Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Romero-Diaz J; Instituto Nacional de Ciencias Médicas y Nutricion, Mexico City, Mexico.
Gordon C; University of Birmingham, Birmingham, UK.
Bae SC; Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
Bernatsky S; McGill University Health Centre, Montreal, Quebec, Canada.
Wallace DJ; Cedars-Sinai Medical Center and University of California, Los Angeles.
Merrill JT; Oklahoma Medical Research Foundation, Oklahoma City.
Isenberg DA; University College London, London, UK.
Rahman A; University College London, London, UK.
Ginzler EM; State University of New York Downstate Medical Center, Brooklyn.
Petri M; Johns Hopkins University School of Medicine, Baltimore, Maryland.
Bruce IN; Manchester Academic Health Sciences Centre, University of Manchester and Central Manchester University Hospitals National Health Service Foundation Trust, Manchester, UK.
Dooley MA; University of North Carolina, Chapel Hill.
Fortin PR; CHU de Québec, Université Laval, Quebec City, Quebec, Canada.
Gladman DD; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
Sanchez-Guerrero J; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
Steinsson K; Landspitali University Hospital, Reykjavik, Iceland.
Ramsey-Goldman R; Northwestern University, Chicago, Illinois.
Khamashta MA; St. Thomas' Hospital, King's College London, London, UK.
Aranow C; Feinstein Institutes for Medical Research, Manhasset, New York.
Mackay M; Feinstein Institutes for Medical Research, Manhasset, New York.
Alarcón GS; University of Alabama at Birmingham.
Manzi S; University of Pittsburgh, Pittsburgh, Pennsylvania.
Nived O; Lund University, Lund, Sweden.
Jönsen A; Lund University, Lund, Sweden.
Zoma AA; Hairmyres Hospital, East Kilbride, Scotland, UK.
van Vollenhoven RF; University of Amsterdam, Amsterdam, The Netherlands.
Ramos-Casals M; Hospital Clinic of Barcelona, Barcelona, Spain.
Ruiz-Irastorza G; Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain.
Lim SS; Emory University, Atlanta, Georgia.
Kalunian KC; University of California Los Angeles, La Jolla.
Inanc M; Istanbul University, Istanbul, Turkey.
Kamen DL; Medical University of South Carolina, Charleston.
Peschken CA; University of Manitoba, Winnipeg, Manitoba, Canada.
Jacobsen S; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Askanase A; Hospital for Joint Diseases, New York University Seligman Center for Advanced Therapeutics, New York, New York.
Farewell V; University of Cambridge, Cambridge, UK.
Stoll T; Kantousspital, Schaffhausen, Switzerland.
Buyon J; New York University, New York, New York.
Clarke AE; University of Calgary, Alberta, Canada.; Pokaż więcej
Źródło :: Arthritis care & research [Arthritis Care Res (Hoboken)] 2020 Dec; Vol. 72 (12), pp. 1800-1808.
Typ publikacji :: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Drug Costs*
Antirheumatic Agents/*economics
Antirheumatic Agents/*therapeutic use
Glucocorticoids/*economics
Glucocorticoids/*therapeutic use
Immunosuppressive Agents/*economics
Immunosuppressive Agents/*therapeutic use
Lupus Erythematosus, Systemic/*drug therapy
Lupus Erythematosus, Systemic/*economics
Adult ; Antirheumatic Agents/adverse effects ; Cost-Benefit Analysis ; Disease Progression ; Female ; Glucocorticoids/adverse effects ; Humans ; Immunosuppressive Agents/adverse effects ; Longitudinal Studies ; Lupus Erythematosus, Systemic/diagnosis ; Male ; Middle Aged ; Models, Economic ; Remission Induction ; Time Factors ; Treatment Outcome ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Autorzy :: Meuth SG; Abteilung für Neurologie, Universitätsklinikum Münster , Münster, Germany.
Bayas A; Klinik für Neurologie und Klinische Neurophysiologie, Universitätsklinikum Augsburg , Germany.
Kallmann B; Multiple Sklerose Zentrum Bamberg , Germany.
Kleinschnitz C; Klinik für Neurologie, Universitätsklinikum Essen , Germany.
Linker R; Klinik und Poliklinik für Neurologie, Universitätsklinikum Regensburg , Germany.
Rieckmann P; Abteilung für Neurologie, Medical Park Loipl , Germany.
Mäurer M; Klinik für Neurologie, Juliusspital Würzburg Klinikum Würzburg Mitte gGmbH , Germany.; Pokaż więcej
Źródło :: Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Nov; Vol. 21 (16), pp. 1965-1969. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Cladribine/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Multiple Sclerosis/*drug therapy
Administration, Oral ; Cladribine/administration & dosage ; Cladribine/adverse effects ; Clinical Trials as Topic ; Drug Administration Schedule ; Drug Monitoring ; Expert Testimony ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Multiple Sclerosis/immunology ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/immunology ; Practice Guidelines as Topic ; Recurrence ; Tablets ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Immunopathogenesis and treatment of cytokine storm in COVID-19.
Autorzy :: Kim JS; Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Lee JY; Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Yang JW; Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Lee KH; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.
Effenberger M; Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria.
Szpirt W; Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Kronbichler A; Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.
Shin JI; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.; Pokaż więcej
Źródło :: Theranostics [Theranostics] 2021 Jan 01; Vol. 11 (1), pp. 316-329. Date of Electronic Publication: 2021 Jan 01 (Print Publication: 2021).
Typ publikacji :: Journal Article; Review
MeSH Terms :: Anti-Inflammatory Agents/*therapeutic use
COVID-19/*complications
Cytokine Release Syndrome/*immunology
Cytokines/*metabolism
Immunosuppressive Agents/*therapeutic use
Anti-Inflammatory Agents/pharmacology ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Azetidines/pharmacology ; Azetidines/therapeutic use ; COVID-19/drug therapy ; COVID-19/immunology ; COVID-19/virology ; Clinical Trials as Topic ; Cytokine Release Syndrome/drug therapy ; Cytokines/antagonists & inhibitors ; Cytokines/immunology ; Humans ; Immunosuppressive Agents/pharmacology ; Interleukin 1 Receptor Antagonist Protein/pharmacology ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Janus Kinases/antagonists & inhibitors ; Janus Kinases/metabolism ; Purines/pharmacology ; Purines/therapeutic use ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use ; SARS-CoV-2/immunology ; STAT Transcription Factors/antagonists & inhibitors ; STAT Transcription Factors/metabolism ; Severity of Illness Index ; Signal Transduction/drug effects ; Signal Transduction/immunology ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.
Autorzy :: Seydoux C; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Medinger M; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Gerull S; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Halter J; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Heim D; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Chalandon Y; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Levrat SM; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Schanz U; Department of Medical Oncology and Hematology, Stem-/Immune- cell-transplant Unit, University Hospital of Zurich, Zurich, Switzerland.
Nair G; Department of Medical Oncology and Hematology, Stem-/Immune- cell-transplant Unit, University Hospital of Zurich, Zurich, Switzerland.
Ansari M; Department Women, Children and Adolescent, Unit of Oncology and Hematology Pediatric, University Hospital of Geneva, Geneva, Switzerland.; Cansearch Research Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Simon P; Clinical Trials Unit, Department of Clinical Research, Basel University, Basel, Switzerland.
Passweg JR; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Cantoni N; Division of Oncology, Hematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland.; Pokaż więcej
Źródło :: Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 209-216. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :: Busulfan/*administration & dosage
Cyclophosphamide/*administration & dosage
Hematologic Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Immunosuppressive Agents/*administration & dosage
Transplantation Conditioning/*methods
Adult ; Aged ; Busulfan/adverse effects ; Chemical and Drug Induced Liver Injury/diagnosis ; Chemical and Drug Induced Liver Injury/mortality ; Cyclophosphamide/adverse effects ; Drug Therapy, Combination ; Female ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/mortality ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Prospective Studies ; Transplantation Conditioning/mortality ; Transplantation, Homologous/methods ; Transplantation, Homologous/mortality ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
Autorzy :: Hawke S; Vascular Immunology Unit, Discipline of Pathology, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia; Central West Neurology and Neurosurgery, Orange, NSW, Australia. Electronic address: .
Zinger A; Vascular Immunology Unit, Discipline of Pathology, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Juillard PG; Vascular Immunology Unit, Discipline of Pathology, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Holdaway K; Beckman-Coulter, Australia.
Byrne SN; The University of Sydney, School of Medical Sciences, Faculty of Medicine and Health, The Westmead Institute for Medical Research, Westmead, NSW, Australia.
Grau GE; Vascular Immunology Unit, Discipline of Pathology, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.; Pokaż więcej
Źródło :: Journal of neuroimmunology [J Neuroimmunol] 2020 Dec 15; Vol. 349, pp. 577392. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Fingolimod Hydrochloride/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Lymphocyte Subsets/*drug effects
Multiple Sclerosis/*blood
Multiple Sclerosis/*drug therapy
Transendothelial and Transepithelial Migration/*drug effects
Cell Movement/drug effects ; Cell Movement/physiology ; Cells, Cultured ; Female ; Fingolimod Hydrochloride/pharmacology ; Humans ; Immunosuppressive Agents/pharmacology ; Lymphocyte Subsets/metabolism ; Male ; Transendothelial and Transepithelial Migration/physiology ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients.
Autorzy :: Yilmaz V; Department of Physiology, Istanbul University, Turkey; Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.. Electronic address: .
Tuzun E; Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Durmus H; Department of Neurology, Istanbul Medical Faculty, Istanbul University, Turkey.
Oflazer P; Department of Neurology, Istanbul Medical Faculty, Istanbul University, Turkey.
Aysal F; Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatric and Neurological Diseases, Turkey.
Parman Y; Department of Neurology, Istanbul Medical Faculty, Istanbul University, Turkey.
Gungor-Tuncer O; Department of Neurology, Sisli Florence Nightingale Hospital, Demiroglu Bilim University, Turkey.
Deymeer F; Department of Neurology, Istanbul Medical Faculty, Istanbul University, Turkey.
Saruhan-Direskeneli G; Department of Physiology, Istanbul University, Turkey.; Pokaż więcej
Źródło :: Journal of neuroimmunology [J Neuroimmunol] 2020 Dec 15; Vol. 349, pp. 577402. Date of Electronic Publication: 2020 Sep 21.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: B-Lymphocytes/*drug effects
B-Lymphocytes/*metabolism
Immunosuppressive Agents/*therapeutic use
Myasthenia Gravis/*blood
Myasthenia Gravis/*drug therapy
Adolescent ; Adult ; Aged ; Biomarkers/blood ; Child ; Female ; Humans ; Immunosuppressive Agents/pharmacology ; Male ; Middle Aged ; Myasthenia Gravis/diagnosis ; Treatment Outcome ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant).
Autorzy :: Koga T; Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology.; Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Takemori S; Nagasaki University Hospital, Clinical Research Center, Nagasaki.
Hagimori N; Nagasaki University Hospital, Clinical Research Center, Nagasaki.; Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan.
Morimoto S; Nagasaki University Hospital, Clinical Research Center, Nagasaki.
Sumiyoshi R; Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology.; Nagasaki University Hospital, Clinical Research Center, Nagasaki.
Shimizu T; Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology.; Nagasaki University Hospital, Clinical Research Center, Nagasaki.
Hosogaya N; Nagasaki University Hospital, Clinical Research Center, Nagasaki.
Fukushima C; Nagasaki University Hospital, Clinical Research Center, Nagasaki.
Yamamoto H; Nagasaki University Hospital, Clinical Research Center, Nagasaki.
Kawakami A; Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2020 Dec 11; Vol. 99 (50), pp. e23291.
Typ publikacji :: Clinical Trial Protocol; Journal Article
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
Castleman Disease/*drug therapy
Immunosuppressive Agents/*therapeutic use
Sirolimus/*therapeutic use
Double-Blind Method ; Humans ; Immunosuppressive Agents/adverse effects ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Sirolimus/adverse effects ; Treatment Failure ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial.
Autorzy :: McGillicuddy JW; Medical University of South Carolina, Charleston, SC, USA.
Chandler JL; Medical University of South Carolina, Charleston, SC, USA.
Sox LR; Medical University of South Carolina, Charleston, SC, USA.
Taber DJ; Medical University of South Carolina, Charleston, SC, USA.; Pokaż więcej
Źródło :: The Annals of pharmacotherapy [Ann Pharmacother] 2020 Dec; Vol. 54 (12), pp. 1185-1193. Date of Electronic Publication: 2020 Jun 08.
Typ publikacji :: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :: Kidney Transplantation*
Drug Monitoring/*methods
Graft Rejection/*prevention & control
Immunosuppressive Agents/*administration & dosage
Medication Adherence/*statistics & numerical data
Tacrolimus/*administration & dosage
Adult ; Drug Monitoring/statistics & numerical data ; Electronic Health Records ; Female ; Graft Rejection/epidemiology ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Prospective Studies ; Reminder Systems/statistics & numerical data ; Risk Factors ; Tacrolimus/therapeutic use ; Telemedicine
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial.
Autorzy :: Sparks JA; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Dellaripa PF; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Glynn RJ; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Paynter NP; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Xu C; Brigham and Women's Hospital, Boston, Massachusetts.
Ridker PM; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Solomon DH; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Pokaż więcej
Źródło :: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2020 Dec; Vol. 72 (12), pp. 2065-2071. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji :: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Immunosuppressive Agents/*adverse effects
Methotrexate/*adverse effects
Pneumonia/*chemically induced
Adult ; Age Factors ; Cardiovascular Diseases/prevention & control ; Double-Blind Method ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Inflammation/prevention & control ; Male ; Methotrexate/therapeutic use ; Middle Aged ; Risk Factors ; Sex Factors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Infliximab treatment in refractory vascular Behcet's disease: A single-center experience.
Autorzy :: Kehribar DY; Ondokuz Mayis University Faculty of Medicine Körfez Mahallesi Atakum Samsun, samsun 55139 Turkey.
Ozgen M; Ondokuz Mayis Universitesi Tip Fakultesi Samsun, Turkey.; Pokaż więcej
Źródło :: Vascular [Vascular] 2020 Dec; Vol. 28 (6), pp. 829-833. Date of Electronic Publication: 2020 May 23.
Typ publikacji :: Journal Article
MeSH Terms :: Behcet Syndrome/*drug therapy
Immunosuppressive Agents/*therapeutic use
Infliximab/*therapeutic use
Adult ; Aged ; Behcet Syndrome/diagnosis ; Behcet Syndrome/immunology ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Infliximab/adverse effects ; Male ; Middle Aged ; Remission Induction ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Turkey ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak.
Autorzy :: Veenstra J; Department of Dermatology, Henry Ford Health System, Detroit, Michigan. Electronic address: .
Buechler CR; Wayne State University School of Medicine, Detroit, Michigan.
Robinson G; Department of Dermatology, Henry Ford Health System, Detroit, Michigan.
Chapman S; Department of Dermatology, Henry Ford Health System, Detroit, Michigan.
Adelman M; Wayne State University School of Medicine, Detroit, Michigan.
Tisack A; Wayne State University School of Medicine, Detroit, Michigan.
Dimitrion P; Wayne State University School of Medicine, Detroit, Michigan.
Todter E; Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan.
Kohen L; Department of Dermatology, Henry Ford Health System, Detroit, Michigan.
Lim HW; Department of Dermatology, Henry Ford Health System, Detroit, Michigan.; Pokaż więcej
Źródło :: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Dec; Vol. 83 (6), pp. 1696-1703. Date of Electronic Publication: 2020 Jul 28.
Typ publikacji :: Journal Article
MeSH Terms :: Autoimmune Diseases/*drug therapy
Coronavirus Infections/*epidemiology
Immunosuppressive Agents/*administration & dosage
Pneumonia, Viral/*epidemiology
Adult ; Aged ; Autoimmune Diseases/immunology ; Betacoronavirus/immunology ; Betacoronavirus/isolation & purification ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques/statistics & numerical data ; Coronavirus Infections/diagnosis ; Coronavirus Infections/immunology ; Coronavirus Infections/virology ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Incidence ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/immunology ; Pneumonia, Viral/virology ; Retrospective Studies ; Risk Assessment/statistics & numerical data ; SARS-CoV-2 ; Severity of Illness Index ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Association of Epstein-Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with autoimmune diseases.
Autorzy :: Fujimoto K; Department of Hematology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.; Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Hatanaka KC; Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Hatanaka Y; Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Kasahara I; Department of Hematology, Sapporo City General Hospital, Sapporo, Hokkaido, Japan.
Yamamoto S; Department of Hematology, Sapporo City General Hospital, Sapporo, Hokkaido, Japan.
Tsuji T; Department of Pathology, Sapporo City General Hospital, Sapporo, Hokkaido, Japan.
Nakata M; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Takakuwa Y; Department of Pathology, NTT Sapporo Medical Center, Sapporo, Hokkaido, Japan.
Haseyama Y; Department of Hematology, Tonan Hospital, Sapporo, Hokkaido, Japan.
Oyamada Y; Department of Pathology, Tonan Hospital, Sapporo, Hokkaido, Japan.
Yonezumi M; Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Suzuki H; Department of Pathology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Sakai H; Department of Hematology, Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan.
Noguchi H; Department of Pathology, Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan.
Mori A; Blood Disorders Center, Aiiku Hospital, Sapporo, Hokkaido, Japan.
Nishihara H; Department of Translational Pathology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Teshima T; Department of Hematology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Matsuno Y; Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.; Pokaż więcej
Źródło :: Hematological oncology [Hematol Oncol] 2020 Dec; Vol. 38 (5), pp. 799-807. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :: Journal Article
MeSH Terms :: Autoimmune Diseases/*complications
Epstein-Barr Virus Infections/*complications
Epstein-Barr Virus Infections/*virology
Herpesvirus 4, Human/*drug effects
Herpesvirus 4, Human/*physiology
Immunologic Deficiency Syndromes/*complications
Immunosuppressive Agents/*adverse effects
Lymphoproliferative Disorders/*diagnosis
Lymphoproliferative Disorders/*etiology
Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Autoimmune Diseases/drug therapy ; Biomarkers ; Female ; Humans ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Immunoglobulin M/blood ; Immunoglobulin M/immunology ; Immunologic Deficiency Syndromes/drug therapy ; Immunosuppressive Agents/therapeutic use ; Lymphoproliferative Disorders/therapy ; Male ; Middle Aged ; Odds Ratio ; Patient Outcome Assessment ; Severity of Illness Index
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience.
Autorzy :: Al-Darzi W; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Aurora L; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Michaels A; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Cowger J; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Grafton G; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Selektor Y; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Tita C; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Hannawi B; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Lanfear D; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Nemeh HW; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
Williams CT; Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.; Pokaż więcej
Źródło :: Clinical transplantation [Clin Transplant] 2020 Dec; Vol. 34 (12), pp. e14091. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :: Heart Transplantation*
Immunocompromised Host*
COVID-19/*immunology
Immunosuppressive Agents/*adverse effects
Postoperative Complications/*immunology
Adult ; Aged ; COVID-19/diagnosis ; COVID-19/etiology ; COVID-19/therapy ; COVID-19 Testing ; Combined Modality Therapy ; Female ; Graft Rejection/prevention & control ; Hospitalization ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Michigan ; Middle Aged ; Postoperative Complications/diagnosis ; Postoperative Complications/therapy ; Postoperative Complications/virology ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Autorzy :: Floris A; AOU University Clinic of Cagliari, Monserrato, Italy.
Piga M; AOU University Clinic of Cagliari, Monserrato, Italy.
Perra D; AOU University Clinic of Cagliari, Monserrato, Italy.
Chessa E; AOU University Clinic of Cagliari, Monserrato, Italy.
Congia M; AOU University Clinic of Cagliari, Monserrato, Italy.
Mathieu A; AOU University Clinic of Cagliari, Monserrato, Italy.
Cauli A; AOU University Clinic of Cagliari, Monserrato, Italy.; Pokaż więcej
Źródło :: Arthritis care & research [Arthritis Care Res (Hoboken)] 2020 Dec; Vol. 72 (12), pp. 1794-1799. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji :: Comparative Study; Journal Article
MeSH Terms :: Antirheumatic Agents/*therapeutic use
Glucocorticoids/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Lupus Erythematosus, Systemic/*drug therapy
Adult ; Antirheumatic Agents/adverse effects ; Disease Progression ; Female ; Glucocorticoids/adverse effects ; Humans ; Immunosuppressive Agents/adverse effects ; Longitudinal Studies ; Lupus Erythematosus, Systemic/diagnosis ; Male ; Remission Induction ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Immunomodulatory activity of a novel polysaccharide extracted from Huangshui on THP-1 cells through NO production and increased IL-6 and TNF-α expression.
Autorzy :: Huo J; School of Food Science and Engineering, South China University of Technology, Guangzhou 510640, China; Key Laboratory of Brewing Molecular Engineering of China Light Industry, Beijing Technology and Business University, Beijing 100048, China; Beijing Laboratory of Food Quality and Safety, Beijing Technology and Business University, Beijing 100048, China.
Wu J; Key Laboratory of Brewing Molecular Engineering of China Light Industry, Beijing Technology and Business University, Beijing 100048, China; Beijing Laboratory of Food Quality and Safety, Beijing Technology and Business University, Beijing 100048, China. Electronic address: .
Zhao M; School of Food Science and Engineering, South China University of Technology, Guangzhou 510640, China.
Sun W; School of Food Science and Engineering, South China University of Technology, Guangzhou 510640, China.
Sun J; Key Laboratory of Brewing Molecular Engineering of China Light Industry, Beijing Technology and Business University, Beijing 100048, China; Beijing Laboratory of Food Quality and Safety, Beijing Technology and Business University, Beijing 100048, China.
Li H; Key Laboratory of Brewing Molecular Engineering of China Light Industry, Beijing Technology and Business University, Beijing 100048, China; Beijing Laboratory of Food Quality and Safety, Beijing Technology and Business University, Beijing 100048, China.
Huang M; Key Laboratory of Brewing Molecular Engineering of China Light Industry, Beijing Technology and Business University, Beijing 100048, China; Beijing Laboratory of Food Quality and Safety, Beijing Technology and Business University, Beijing 100048, China. Electronic address: .; Pokaż więcej
Źródło :: Food chemistry [Food Chem] 2020 Nov 15; Vol. 330, pp. 127257. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji :: Journal Article
MeSH Terms :: Immunosuppressive Agents/*pharmacology
Interleukin-6/*metabolism
Nitric Oxide/*biosynthesis
Polysaccharides/*pharmacology
Rivers/*chemistry
Tumor Necrosis Factor-alpha/*metabolism
Humans ; Immunosuppressive Agents/chemistry ; Molecular Weight ; Polysaccharides/chemistry ; THP-1 Cells
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Dosing algorithm for Tacrolimus in Tunisian Kidney transplant patients: Effect of CYP 3A4*1B and CYP3A4*22 polymorphisms.
Autorzy :: Ben-Fredj N; Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Tunisia.
Hannachi I; Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Tunisia; Faculty of Sciences of Bizerte, Carthage University, Tunisia. Electronic address: .
Chadli Z; Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Tunisia.
Ben-Romdhane H; Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Tunisia.
A Boughattas N; Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Tunisia.
Ben-Fadhel N; Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Tunisia.
Aouam K; Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Tunisia.; Pokaż więcej
Źródło :: Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2020 Nov 15; Vol. 407, pp. 115245. Date of Electronic Publication: 2020 Sep 17.
Typ publikacji :: Journal Article
MeSH Terms :: Algorithms*
Kidney Transplantation*
Cytochrome P-450 CYP3A/*genetics
Immunosuppressive Agents/*administration & dosage
Tacrolimus/*administration & dosage
Adult ; Cross-Sectional Studies ; Female ; Genotype ; Humans ; Immunosuppressive Agents/therapeutic use ; Isoenzymes/genetics ; Linear Models ; Male ; Middle Aged ; Models, Theoretical ; Reproducibility of Results ; Tacrolimus/therapeutic use ; Tunisia ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease.
Autorzy :: Sebastian S; IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.; Hull York Medical School, Hull, UK.
Gonzalez HA; IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.
Peyrin-Biroulet L; Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-Les-Nancy, France.; Inserm U1256 NGERE, Lorraine University, Vandoeuvre-Les-Nancy, France.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Nov 07; Vol. 14 (11), pp. 1632-1643.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Immunocompromised Host*
Coronavirus Infections/*immunology
Immunosuppressive Agents/*adverse effects
Inflammatory Bowel Diseases/*drug therapy
Coronavirus Infections/complications ; Global Health ; Humans ; Immunosuppressive Agents/therapeutic use ; Inflammatory Bowel Diseases/complications ; Inflammatory Bowel Diseases/immunology ; Pandemics ; Patient Safety ; Risk Factors ; Severity of Illness Index
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone.
Autorzy :: Brazzelli V; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
Isoletta E; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
Barak O; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
Barruscotti S; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
Vassallo C; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
Giorgini C; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
Michelerio A; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
Tomasini CF; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
Musella V; Unit of Clinical Epidemiology and Biometrics, Scientific Direction, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Klersy C; Unit of Clinical Epidemiology and Biometrics, Scientific Direction, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.; Pokaż więcej
Źródło :: Dermatologic therapy [Dermatol Ther] 2020 Nov; Vol. 33 (6), pp. e14516. Date of Electronic Publication: 2020 Nov 17.
Typ publikacji :: Comparative Study; Journal Article; Observational Study
MeSH Terms :: Biological Products/*administration & dosage
COVID-19/*epidemiology
Dermatologic Agents/*administration & dosage
Immunosuppressive Agents/*administration & dosage
Psoriasis/*drug therapy
Adult ; Aged ; Biological Products/adverse effects ; COVID-19/immunology ; Dermatologic Agents/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Immunocompromised Host ; Immunosuppressive Agents/adverse effects ; Italy/epidemiology ; Male ; Middle Aged ; Prevalence ; Prospective Studies ; Psoriasis/epidemiology ; Psoriasis/immunology ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""IMMUNOSUPPRESSIVE agents"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język